Definium Therapeutics (DFTX) executive compensation, 2026 proxy

Robert Barrow, Chief Executive Officer, was paid $12.8M in 2025, up 378% from $2.7M the year before.

Filed
April 27, 2026
Annual meeting
June 11, 2026
Pay year
2025
Named executives
3
CEO total pay
$12.8M+378% vs prior year
CEO pay in equity
92%$11.7M in awards
CEO 2025 Total Compensation
$12,767,442Increase from prior year
CEO Base Salary
$655,0004% increase from 2024
Corporate Bonus Payout
105%Based on 2025 performance
CEO Target Bonus
55%Percentage of base salary
PSU Share of CEO Equity
68%Portion of 2025 grant

How Barrow was paid

$12.8M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary5%Stock awards92%Non-equity incentive3%All other compensation0%

Named executive officers

ExecutiveTotal
Robert BarrowChief Executive Officer$12,767,442
Brandi L. RobertsChief Financial Officer$5,116,362
Daniel Karlin, M.D.Chief Medical Officer$4,001,258

What changed and why

  • $12.8MChief Executive Officer Robert Barrow received total compensation of $12,767,442 in fiscal 2025.
  • 4%Robert Barrow's base salary increased by approximately 4% to $655,000 for fiscal 2025.
  • 105%The annual performance bonus was funded at 105% based on overall corporate goal achievements.
  • Long-term incentives were expanded to introduce performance-based restricted stock units.
  • 68%Approximately 68% of Robert Barrow's 2025 equity grant consisted of performance stock units.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.